Free Trial
NASDAQ:EQ

Equillium (EQ) Stock Price, News & Analysis

Equillium logo
$0.44 -0.03 (-7.02%)
As of 04/25/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Equillium Stock (NASDAQ:EQ)

Key Stats

Today's Range
$0.43
$0.46
50-Day Range
$0.39
$0.90
52-Week Range
$0.36
$1.89
Volume
66,992 shs
Average Volume
360,588 shs
Market Capitalization
$15.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00
Consensus Rating
Hold

Company Overview

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Equillium Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
55th Percentile Overall Score

EQ MarketRank™: 

Equillium scored higher than 55% of companies evaluated by MarketBeat, and ranked 421st out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Equillium has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Equillium has only been the subject of 2 research reports in the past 90 days.

  • Read more about Equillium's stock forecast and price target.
  • Earnings Growth

    Earnings for Equillium are expected to decrease in the coming year, from $0.14 to ($0.81) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Equillium is -3.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Equillium is -3.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Equillium has a P/B Ratio of 0.68. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Equillium's valuation and earnings.
  • Percentage of Shares Shorted

    1.10% of the float of Equillium has been sold short.
  • Short Interest Ratio / Days to Cover

    Equillium has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Equillium has recently decreased by 31.46%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Equillium does not currently pay a dividend.

  • Dividend Growth

    Equillium does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.10% of the float of Equillium has been sold short.
  • Short Interest Ratio / Days to Cover

    Equillium has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Equillium has recently decreased by 31.46%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Equillium has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.02 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for Equillium this week, compared to 1 article on an average week.
  • Search Interest

    1 people have searched for EQ on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Equillium insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    30.30% of the stock of Equillium is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 27.05% of the stock of Equillium is held by institutions.

  • Read more about Equillium's insider trading history.
Receive EQ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Equillium and its competitors with MarketBeat's FREE daily newsletter.

EQ Stock News Headlines

Equillium says FDA declines Breakthrough Therapy designation for itolizumab
Trump Treasure April 19
Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly that, just 12 months later…
Equillium shares fall following FDA feedback
Equillium (NASDAQ:EQ) Stock Price Down 3.7% - Should You Sell?
Equillium downgraded to Market Perform from Outperform at Leerink
See More Headlines

EQ Stock Analysis - Frequently Asked Questions

Equillium's stock was trading at $0.7482 at the beginning of 2025. Since then, EQ stock has decreased by 41.4% and is now trading at $0.4383.
View the best growth stocks for 2025 here
.

Equillium, Inc. (NASDAQ:EQ) announced its quarterly earnings data on Thursday, March, 27th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.06. The business had revenue of $4.39 million for the quarter. Equillium had a negative trailing twelve-month return on equity of 20.68% and a negative net margin of 10.05%.

Equillium (EQ) raised $70 million in an initial public offering (IPO) on Friday, October 12th 2018. The company issued 4,700,000 shares at a price of $14.00-$16.00 per share. Jefferies, Leerink Partners and Stifel served as the underwriters for the IPO.

Shares of EQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Equillium investors own include NVIDIA (NVDA), Meta Platforms (META), Bank of America (BAC), Advanced Micro Devices (AMD), AbbVie (ABBV), Tilray (TLRY) and Carnival Co. & (CCL).

Company Calendar

Last Earnings
3/27/2025
Today
4/26/2025
Next Earnings (Estimated)
5/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:EQ
Fax
N/A
Employees
40
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$3.00
High Stock Price Target
$5.00
Low Stock Price Target
$1.00
Potential Upside/Downside
+584.5%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
3.13
P/E Growth
N/A
Net Income
$-13,340,000.00
Pretax Margin
-10.02%

Debt

Sales & Book Value

Annual Sales
$41.10 million
Price / Cash Flow
N/A
Book Value
$0.64 per share
Price / Book
0.68

Miscellaneous

Free Float
24,695,000
Market Cap
$15.66 million
Optionable
Not Optionable
Beta
1.87
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NASDAQ:EQ) was last updated on 4/27/2025 by MarketBeat.com Staff
From Our Partners